The Ledger

ILMN

Illumina IncHealth Careinsider_universe

Last close $179.53Jun 28, 2026

Day +1.69%

Currently held

Agent 2 — Adaptivelong
91 sh @ $167.94 · stop $138.05
+$1,070.59 unrealized

Everything we've seen

·Jun 29, 1:46 PMstreamnews
Guggenheim Maintains Buy on Illumina, Raises Price Target to $200
Guggenheim analyst Subbu Nambi maintains Illumina (NASDAQ:ILMN) with a Buy and raises the price target from $180 to $200.
!Jun 29, 9:51 AMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 29, 7:06 AMsignal
Agent 6 — Options Momentum — insufficient_capital
❖Jun 29, 5:59 AMnewsvia finnhub
Guggenheim Maintains Buy on Illumina, Raises Price Target to $200
Guggenheim analyst Subbu Nambi maintains Illumina (NASDAQ:ILMN) with a Buy and raises the price target from $180 to $200.
?Jun 26, 6:04 PMdecisionconsidered
Agent 1 — Immutable — considered
Stage 2: close $176.55 > MA150 $136.80 (+29.1%), MA rising, 3.4% off 52w high, vol 1.00× avg
!Jun 26, 12:49 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 26, 11:51 AMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 26, 10:48 AMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 26, 10:35 AMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 26, 10:21 AMsignal
Agent 6 — Options Momentum — insufficient_capital
❖Jun 26, 10:20 AMnewsvia finnhub
The Disinflation Trade Has A New Address: Genomics
For the last two weeks, the headline has been a rotation out of mega-cap tech. The money split into baskets. This week, one of those baskets resolved into focus: genomics.
!Jun 26, 9:50 AMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 26, 9:35 AMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 26, 9:17 AMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 26, 7:03 AMsignal
Agent 6 — Options Momentum — insufficient_capital
❖Jun 26, 5:37 AMnewsvia finnhub
Bernstein Reinstates Market Perform on Illumina, Announces $185 Price Target
Bernstein analyst Eve Burstein reinstates Illumina (NASDAQ:ILMN) with a Market Perform and announces $185 price target.
!Jun 25, 5:47 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 25, 5:31 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 25, 5:16 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 25, 5:06 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 25, 4:47 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 25, 4:32 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 25, 4:21 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 25, 3:47 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 25, 3:33 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 25, 3:17 PMsignal
Agent 6 — Options Momentum — insufficient_capital
❖Jun 25, 3:00 PMnewsvia finnhub
Alger Russell Innovation Index Updates for Second Quarter 2026
Fred Alger Management, LLC ("Alger"), a privately held growth equity investment manager, today announced the quarterly rebalancing of the Alger Russell Innovation Index ("Index"). Following the close of trading on Friday, June 26, 2026, the Index will be rebalanced, and the following changes will be effective.
!Jun 25, 2:48 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 25, 2:35 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 25, 2:20 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 25, 1:47 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 25, 1:35 PMsignal
Agent 6 — Options Momentum — insufficient_capital
?Jun 25, 10:16 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ILMN is up 3.20% today with no attributable headline, suggesting institutional flow or sector rotation rather than a news-driven spike. With 329 minutes remaining there is ample time for continuation, but the absence of a catalyst raises the risk of a mean-reversion fade as the session progresses. The macro context shows T10YIE at 2.4σ below trend — compressed inflation expectations favor long-duration and growth-sensitive names like ILMN, which is a mild tailwind. However, the move is already at the upper end of the 2-5% range where profit-taking typically emerges intraday, and without a confirming news driver the conviction for further extension is moderate at best. No reversal pattern is evident from the data provided. Net assessment: slight edge to continuation given macro support and ample time, but no strong conviction signal — probability held near the lower end of the continuation range.
!Jun 25, 10:16 AMsignalseverity 0.03
Agent 7 — Day Trader — day_trade_skipped
ILMN is up 3.20% today with no attributable headline, suggesting institutional flow or sector rotation rather than a news-driven spike. With 329 minutes remaining there is ample time for continuation, but the absence of a catalyst raises the risk of a mean-reversion fade as the session progresses. The macro context shows T10YIE at 2.4σ below trend — compressed inflation expectations favor long-duration and growth-sensitive names like ILMN, which is a mild tailwind. However, the move is already at the upper end of the 2-5% range where profit-taking typically emerges intraday, and without a confirming news driver the conviction for further extension is moderate at best. No reversal pattern is evident from the data provided. Net assessment: slight edge to continuation given macro support and ample time, but no strong conviction signal — probability held near the lower end of the continuation range.
✓Jun 25, 9:31 AMdecisionacted
Agent 2 — Adaptive — pyramid
Pyramid add-on fired at +10.32% unrealized. Added 30 sh @ $179.17 ($5375.10). Position now 91 sh @ weighted avg $167.94.
!Jun 25, 9:21 AMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 25, 7:03 AMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 24, 6:05 PMsignal
Agent 6 — Options Momentum — insufficient_capital
?Jun 24, 6:01 PMdecisionconsidered
Agent 1 — Immutable — considered
Stage 2: close $174.99 > MA150 $136.05 (+28.6%), MA rising, 1.6% off 52w high, vol 1.05× avg
❖Jun 24, 2:56 PMnewsvia finnhub
Why Illumina (ILMN) Stock Is Trading Up Today
Shares of genomics company Illumina (NASDAQ:ILMN) jumped 6.6% in the morning session after it appointed a high-profile Eli Lilly executive to its board and a price target increase from Barclays.
❖Jun 24, 9:16 AMnewsvia finnhub
Illumina (ILMN) Stock After 80% One-Year Rebound Is The Price Now Justified
How Illumina's Recent Moves Frame the Valuation Question Before getting into detailed valuation models, it helps to step back and ask a simple question: based on what you can see today, does Illumina stock look fairly priced, stretched, or potentially mispriced? Illumina recently closed at US$164.93, with returns of 0.4% over the past week, 14.2% over the past month, 22.8% year to date, and 80.2% over the past year, while returns over the last 3 and 5 years show declines of 7.5% and 64.6%...
❖Jun 24, 6:41 AMnewsvia finnhub
Barclays Maintains Underweight on Illumina, Raises Price Target to $145
Barclays analyst Luke Sergott maintains Illumina (NASDAQ:ILMN) with a Underweight and raises the price target from $122 to $145.
❖Jun 23, 9:12 PMnewsvia finnhub
Adding Eli Lilly’s R&D Chief to the Board Might Change The Case For Investing In Illumina (ILMN)
Illumina, Inc. recently expanded its Board from nine to ten members and appointed Daniel M. Skovronsky, M.D., Ph.D., Chief Scientific and Product Officer at Eli Lilly and President of Lilly Research Laboratories, as an independent director effective June 16, 2026. His background in drug discovery, clinical development, and precision medicine across cardiometabolic, immunology, and neuroscience fields aligns closely with Illumina’s push into clinical genomics and multiomics. We’ll now examine...
?Jun 23, 10:25 AMdecisionconsidered
Agent 7 — Day Trader — analyze: fail
Claude analysis failed: Anthropic 529: {"type":"error","error":{"type":"overloaded_error","message":"Overloaded"},"request_id":"req_011CcLLzP1uakKiCA8hAsxX6"}
❖Jun 23, 9:05 AMnewsvia finnhub
Daniel M. Skovronsky, MD, PhD, appointed to Illumina's Board of Directors
Illumina, Inc. (NASDAQ: ILMN) today announced the appointment of Daniel M. Skovronsky, MD, PhD, to its Board of Directors, effective June 16, 2026. Dr. Skovronsky brings extensive experience in drug discovery, clinical development and translational medicine, which are areas directly relevant to Illumina's work advancing genomics and multiomics platforms.
❖Jun 22, 4:30 PMnewsvia finnhub
Alger Russell Innovation Index Updates for Second Quarter 2026
Fred Alger Management, LLC ("Alger"), a privately held growth equity investment manager, today announced the quarterly rebalancing of the Alger Russell Innovation Index ("Index"). Following the close of trading on Friday, June 26, 2026, the Index will be rebalanced, and the following changes will be effective.
❖Jun 21, 1:00 PMnewsvia finnhub
Syntax Bio Announces Expanded Series A and Leadership Appointments
CHICAGO, June 21, 2026--Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced an expanded Series A and new appointments to its executive leadership team, board of directors and scientific advisory board. The expansion brings Syntax Bio’s Series A to $14.4 million and total funding to over $25 million.
❖Jun 19, 3:00 AMnewsvia finnhub
IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist
ESPOO, Finland & MUNICH, June 19, 2026--IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ).
?Jun 18, 7:03 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $10.13 cash available; close=$159.09.
?Jun 18, 7:03 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
ILMN is down 10.2% from its 30-day high with no identifiable fundamental catalyst driving the decline — no negative news headlines, no earnings imminent, and no insider selling. The drop appears largely macro/sector-driven given today's broad risk-off session (SPY -1.25%, VXX +4.39%) and the healthcare sector's recent 5-day underperformance vs. SPY (-3.54pts). Options flow is modestly constructive with a P/C ratio of 0.59 and near-average call/put volumes, suggesting no unusual bearish positioning. VIX at the 34th percentile represents a relatively benign macro backdrop, though the 10Y at 4.43% and today's broad sell-off create near-term headwinds.
?Jun 17, 6:06 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $11.35 cash available; close=$159.09.
?Jun 17, 6:05 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
ILMN is down 10.2% from its 30-day high with no identifiable fundamental catalyst driving the decline — no negative news headlines, no earnings imminent, and no insider selling. The drop appears largely macro/sector-driven given today's broad risk-off session (SPY -1.25%, VXX +4.39%) and the healthcare sector's recent 5-day underperformance vs. SPY (-3.54pts). Options flow is modestly constructive with a P/C ratio of 0.59 and near-average call/put volumes, suggesting no unusual bearish positioning. VIX at the 34th percentile represents a relatively benign macro backdrop, though the 10Y at 4.43% and today's broad sell-off create near-term headwinds.
?Jun 17, 6:05 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
The 10.2% pullback from the 30-day high appears to be driven by broader macro factors rather than company-specific deterioration, as there are no news headlines indicating fundamental issues with ILMN in the window. The macro context shows a flattening yield curve (T10Y2Y at 2.3σ below trend), which tends to weigh on growth-oriented names like Illumina rather than signal company-level problems. However, the absence of any supporting news or catalyst makes it difficult to assign high conviction to a near-term rebound, and the 8-K filing lacks disclosed metrics, leaving some uncertainty about the company's current operating trajectory.
❖Jun 16, 10:17 AMnewsvia finnhub
1 Unpopular Stock That Deserves Some Love and 2 Facing Challenges
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.
?Jun 16, 9:46 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ILMN is down 1.67% today, a modest but real move. There are no news catalysts to explain the move, which means it could be broad market or sector selling, or quiet distribution. The macro context shows the T10Y2Y spread is 2.1σ below its 24-month trend, flagging a flatter/inverted yield curve environment — this is marginally negative for risk/growth assets like ILMN (a genomics/biotech name), which could provide a mild tailwind for continued selling. However, the move is relatively small (under 2%), which limits conviction that large directional flow is driving it. With 359 minutes remaining (essentially a full trading day remaining — this appears to be early session), there is ample time for continuation but also ample time for reversal. No reversal pattern is evident, and absence of news does not disqualify the setup. The combination of a modest downward move, mildly supportive macro backdrop for continuation (growth-negative curve environment), no reversal signal, and plenty of time remaining yields a neutral-to-slight-continuation read. Setting at 0.50 — borderline, resolving in favor of the trade per system rules.
❖Jun 11, 6:30 AMnewsvia finnhub
Global Next Generation Sequencing Services Market Size/Share Worth USD 56.1 Billion by 2035 at a 23.5% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, SWOT Analysis)
[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Next Generation Sequencing Services Market size & share revenue was valued at approximately USD 6.8 Billion in 2025 and is expected to reach USD 8.3 Billion in 2026 and is expected to reach around USD 56.1 Billion by 2035, at a CAGR of 23.5% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Illumina Inc.,
?Jun 10, 8:31 PMdecisionconsidered
Agent 20 — SIR Price/Volume — skip
[distribution] The PV path tells a clear distributive story in two acts. First, a strong accumulation-like surge carried ILMN from $141.51 (2026-05-18) to a climactic $170.93 on 2026-06-03 on 3.1M shares — the highest-volume close in the 20-day window — a volume extreme at a price extreme that reads as exhaustion rather than a durable breakout. Second, and critically, the path since that peak is unambiguously distributive: four consecutive down days (2026-06-03 through 2026-06-08) shed ~13 points on volumes of 2.6M, 2.1M, and 1.3M, while the two subsequent recovery days (2026-06-09: +1.26% on 1.5M; 2026-06-10/today: +1.52% on 2.7M) have only clawed back to $162.47 — still ~5% below the 2026-06-03 peak close. The 2-D path has traced a classic down-and-right distributive arc from the $170.93 high: lower closes accompanied by volume that is still elevated on up days but failing to recapture prior ground, with heavier volume having already occurred on the sell-side cluster ($158–$163 range acting as a ceiling, not a launching pad). Risks: A sustained close back above $170 on volume exceeding the 2026-06-03 3.1M print would invalidate the distributive read and suggest the exhaustion bar was instead a high-volume continuation signal; additionally, today's z-score of 1.59 on an up day is notable — if the next 2–3 sessions show persistent up-day volume dominance above 2.5M while holding above $162, the pattern could be reassessed as re-accumulation rather than distribution.
✓Jun 10, 6:00 PMdecisionacted
Agent 2 — Adaptive — entry
Stage 2: close $162.41 > MA150 $133.44 (+21.7%), MA rising, 8.4% off 52w high, vol 2.43× avg
❖Jun 10, 4:38 PMnewsvia finnhub
Stocks Settle Sharply Lower on Escalating Middle East Tensions
The S&P 500 Index ($SPX ) (SPY ) on Wednesday closed down -1.62%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down -1.87%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -1.98%. June E-mini S&P futures (ESM26 ) fell -1.62%, and June E-mini Nasdaq futures...
❖Jun 10, 3:43 PMnewsvia finnhub
Illumina upgraded to overweight at JPMorgan on clinical demand outlook
Investing.com -- Illumina received a bullish rating upgrade from JPMorgan, which raised its recommendation to Overweight from Neutral and lifted its December 2026 price target to $185 from $125, citing growing confidence in the DNA sequencing company's ability to sustain strong growth despite increasing competition.
?Jun 10, 12:15 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ILMN is up ~3% intraday with no attributable headline, suggesting this is technically or flow-driven rather than a news catalyst. With 210 minutes remaining there is ample time for continuation, but the absence of a clear fundamental catalyst means the move could be fading off an early surge rather than building. The macro backdrop (T10Y2Y at 0.4, 2.1σ below trend) is modestly negative for risk appetite broadly but ILMN as a genomics/healthcare name is not directly in the sectors most reactive to yield curve flattening (banks, defensives), so macro is roughly neutral here. No reversal signal is present, and a ~3% move represents meaningful conviction from whoever initiated it. With no specific reason to fade and adequate time remaining, modest continuation bias is warranted, but the lack of any news anchor and the mid-range magnitude keep this in the ordinary-momentum category rather than a high-conviction setup.
❖Jun 10, 11:21 AMnewsvia finnhub
Stocks Resume Decline as Chipmakers and AI Companies Fall
The S&P 500 Index ($SPX ) (SPY ) today is down -0.61%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.88%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.80%. June E-mini S&P futures (ESM26 ) are down -0.71%, and June E-mini Nasdaq futures...
❖Jun 10, 10:09 AMnewsvia finnhub
Stocks Fall on Weakness in Tech and Trucking Companies
The S&P 500 Index ($SPX ) (SPY ) today is down -0.28%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.38%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.28%. June E-mini S&P futures (ESM26 ) are down -0.25%, and June E-mini Nasdaq futures...
?Jun 10, 9:51 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ILMN is up ~2.79% intraday with no attributable headline, suggesting this is likely flow-driven — possibly institutional positioning, options-related activity, or a sector rotation into genomics/biotech names. The move is meaningful but not extreme, and with 354 minutes remaining (essentially a full trading day still ahead), there is ample time for continuation. The macro backdrop is modestly unfavorable for risk assets given the T10Y2Y reading 2.1σ below trend, which can signal defensive rotation — but ILMN as a growth/biotech name is not directly in the cross-hairs of a yield curve flattening trade. No reversal pattern is evident from the data given. Absence of news does not negate the momentum signal. The setup is ordinary momentum with no strong fade catalyst — probability is modestly above 0.5 in favor of continuation but does not clear the 0.7 bar given lack of confirming catalysts and the mildly risk-off macro tilt.
❖Jun 10, 9:42 AMnewsvia finnhub
Nike downgraded, Oscar Health upgraded: Wall Street's top analyst calls
Nike downgraded, Oscar Health upgraded: Wall Street's top analyst calls
❖Jun 10, 6:38 AMnewsvia finnhub
Nasdaq Futures Plunge as Tech Selloff Deepens, U.S. Inflation Data in Focus
June Nasdaq 100 E-Mini futures (NQM26) are down -1.61% this morning as investors continued to trim exposure to the technology sector, with the focus now turning to key U.S. inflation data.
❖Jun 10, 4:59 AMnewsvia finnhub
JP Morgan Upgrades Illumina to Overweight, Raises Price Target to $185
JP Morgan analyst Casey Woodring upgrades Illumina (NASDAQ:ILMN) from Neutral to Overweight and raises the price target from $125 to $185.
❖Jun 9, 12:25 PMnewsvia finnhub
Samsung Electronics invests $175 million in Element Biosciences' Series E funding round
Privately held Element Biosciences said on Tuesday it had raised funds ‌in an upsized Series E round, ‌including $175 million from longtime investor Samsung Electronics, to expand commercialization of its genetic testing and research products. Element said the financing would support commercialization of its sequencing ⁠products, such as AVITI and VITARI, as well as the upcoming launches of AVITI Dx and AVITI24. Element said the funding would also help expand its international ‌presence and support development of future products for research, drug development and diagnostic uses.
?Jun 9, 12:05 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
ILMN is down 10.8% from its 30-day high without an obvious fundamental impairment — the only recent news is a new product launch (StrataMap Spatial Solution), which is mildly positive. The 8-K filed in May lacks disclosed metrics, making the catalyst for the drop unclear. Health Care sector is showing strong relative strength (rank 2 of 11, outperforming SPY by +2.33pp over 30 days and +5.80pp over 5 days), which suggests the dip is idiosyncratic rather than sector-driven — a caution flag for stock-specific risk. Options flow is below average on both sides (call z=-1.88, put z=-0.97), providing no confirmation signal, and there are no insider purchases to validate a buying thesis.
?Jun 9, 7:02 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $0.00 cash available; close=$158.04.
?Jun 9, 7:02 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
ILMN is down 10.8% from its 30-day high without an obvious fundamental impairment — the only recent news is a new product launch (StrataMap Spatial Solution), which is mildly positive. The 8-K filed in May lacks disclosed metrics, making the catalyst for the drop unclear. Health Care sector is showing strong relative strength (rank 2 of 11, outperforming SPY by +2.33pp over 30 days and +5.80pp over 5 days), which suggests the dip is idiosyncratic rather than sector-driven — a caution flag for stock-specific risk. Options flow is below average on both sides (call z=-1.88, put z=-0.97), providing no confirmation signal, and there are no insider purchases to validate a buying thesis.
?Jun 8, 6:26 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
The 10.8% drop from the 30-day high does not appear linked to fundamental deterioration — the only recent news is a product launch (StrataMap Spatial Solution), which is modestly positive. There is no evidence of guidance cuts, earnings misses, or accounting issues in the available filings. The macro backdrop shows a flattening yield curve (T10Y2Y at 2.5σ below trend), which is a headwind for growth/innovation-oriented names like ILMN but is not company-specific. The drop is more consistent with macro/sector rotation pressure than intrinsic deterioration.
?Jun 8, 6:06 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
The 10.8% drop from the 30-day high does not appear linked to fundamental deterioration — the only recent news is a product launch (StrataMap Spatial Solution), which is modestly positive. There is no evidence of guidance cuts, earnings misses, or accounting issues in the available filings. The macro backdrop shows a flattening yield curve (T10Y2Y at 2.5σ below trend), which is a headwind for growth/innovation-oriented names like ILMN but is not company-specific. The drop is more consistent with macro/sector rotation pressure than intrinsic deterioration.
?Jun 8, 6:05 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $0.00 cash available; close=$158.08.
?Jun 8, 6:05 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip
ILMN is down 10.8% from its 30-day high without an obvious fundamental impairment — the only recent news is a new product launch (StrataMap Spatial Solution), which is mildly positive. The 8-K filed in May lacks disclosed metrics, making the catalyst for the drop unclear. Health Care sector is showing strong relative strength (rank 2 of 11, outperforming SPY by +2.33pp over 30 days and +5.80pp over 5 days), which suggests the dip is idiosyncratic rather than sector-driven — a caution flag for stock-specific risk. Options flow is below average on both sides (call z=-1.88, put z=-0.97), providing no confirmation signal, and there are no insider purchases to validate a buying thesis.
?Jun 8, 1:15 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ILMN is down ~2.91% today, a meaningful move suggesting real selling pressure. The only headline is a product launch (StrataMap Spatial Solution), which is modestly positive but clearly not driving the session — the stock is selling off despite it, suggesting either broader sector rotation or undisclosed selling pressure (institutional distribution, index rebalancing, or macro-driven selling in genomics/biotech). The macro context shows a flattening yield curve (T10Y2Y at 2.5σ below trend), which tends to weigh on growth/innovation names like ILMN that carry high valuation multiples and are sensitive to discount rate expectations. With 150 minutes remaining there is ample time for continuation, but the setup is not a high-conviction momentum read — the product launch headline introduces a mild counter-pressure that could attract dip buyers, and the move is not yet extreme enough to be clearly an 'exhaustion' or 'panic' sell. No strong reversal signals are visible, but no clear catalyst is driving the down move either. Net: modest continuation probability favoring the downside, consistent with the broader flattening macro backdrop pressuring growth equities, but not a high-confidence setup.
?Jun 8, 12:31 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $0.00 cash available; close=$157.72.
?Jun 8, 10:40 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ILMN is down ~1.83% today, which is a moderate but not outsized move. The single headline is a product launch (StrataMap Spatial Solution) which is a mildly positive catalyst — this could act as a headwind against further downside or even attract dip buyers mid-session, as it suggests operational momentum. The macro backdrop (T10Y2Y at 0.38, 2.5σ below trend) is slightly flattening/defensive, which is not particularly bullish for a growth/genomics name like ILMN but isn't a strong directional accelerant either. With 305 minutes remaining there is ample time for continuation, but the positive product news introduces a real reversal risk. The move is below the 2% threshold where momentum conviction becomes clearer. Balancing the modest downward momentum against the mildly positive intraday headline and neutral macro, the setup does not reach the 0.5 continuation threshold — the product launch creates a credible reason to expect at least a partial fade rather than further selling into the close.
❖Jun 8, 9:15 AMnewsvia finnhub
Illumina launches StrataMap Spatial Solution, a powerful end-to-end spatial whole transcriptome research solution
Illumina, Inc. (NASDAQ: ILMN) today announced the launch of the StrataMap Spatial Solution, offering an unmatched breadth of coverage and resolution to redefine what researchers can detect with spatial transcriptomics. StrataMap Spatial, previously called the Illumina Spatial Solution, is an end-to-end sequencing-based research solution to uncover spatial insights. Spatial transcriptomics is already a critical tool in developmental biology, neuroscience, and oncology research. StrataMap Spatial
❖Jun 8, 5:17 AMnewsvia finnhub
Illumina Launches StrataMap Spacial Solution, Expanding Coverage And Resolution Of What Researchers Can Detect With Spatial Transcriptomics
StrataMap Spatial meets the growing demand for scalable spatial biology studies from research and biopharma customers, through features such as:Capture area: The 7.5 cm2 capture area accommodates serial sections for
▣Jun 7, 8:00 PMjournalmanual
Agent 6 — Options Momentum closed long 30 @ $6.89 (+$2.03)
Stop: premium $5.26 ≤ trailing floor $8.11 (peak $10.81 × 0.75)
▣Jun 7, 8:00 PMjournalstop
Agent 6 — Options Momentum closed long 70 @ $10.96 (+$229.92)
Stop: premium $10.96 ≤ trailing floor $16.67 (peak $22.22 × 0.75)
▣Jun 7, 8:00 PMjournalmanual
Agent 6 — Options Momentum closed long 70 @ $18.10 (+$790.03)
Stop: premium $14.25 ≤ trailing floor $16.67 (peak $22.22 × 0.75)
❖Jun 7, 2:08 PMnewsvia finnhub
Illumina (ILMN) Valuation Check After New Oncology Collaborations And MRD Research Launch
Event driven focus on Illumina stock Illumina (ILMN) has drawn fresh attention after announcing a collaboration with Integrated DNA Technologies, the fireflyGO automation platform with SPT Labtech, and a new whole-genome-based MRD research kit for oncology. See our latest analysis for Illumina. These oncology focused launches come after a strong run in the stock, with Illumina’s share price up 14.41% over 30 days and 30.61% over 90 days, while the 1 year total shareholder return of 96.37%...
❖Jun 5, 11:30 AMnewsvia finnhub
Recursion Pharmaceuticals (RXRX) Up 16.2% Since Last Earnings Report: Can It Continue?
Recursion Pharmaceuticals (RXRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
?Jun 5, 10:05 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ILMN is down 3.81% today with no attributed headline, suggesting either institutional selling or sector/market-driven pressure. The move is meaningful in magnitude and represents real conviction from sellers. With 340 minutes remaining (essentially the full afternoon session), there is ample time for the move to extend further into the close. The macro context shows the yield curve (T10Y2Y at 0.42, 1.9σ below trend) in a flattening posture, which is generally unhelpful for growth/genomics names like ILMN that depend on risk appetite and easy financial conditions. No news catalyst present, but absence of news doesn't negate momentum — large-cap biotech/genomics names can see sustained selling on fund flows, index rebalancing, or broad sector rotation. No evidence of reversal pattern or fade from lows described. The setup is ordinary momentum with a modestly supportive macro headwind for the name, warranting a continuation read slightly above the 0.5 threshold but not a high-conviction call given no specific catalyst.
?Jun 4, 6:00 PMdecisionconsidered
Agent 2 — Adaptive — considered
Stage 2: close $168.06 > MA150 $132.08 (+27.2%), MA rising, 5.2% off 52w high, vol 1.39× avg
❖Jun 4, 12:35 PMnewsvia finnhub
Is Grail Stock a Bad-News Buy After Its Recent Pullback?
The cancer test maker could still have a bright future.
❖Jun 4, 11:30 AMnewsvia finnhub
Why Is Editas (EDIT) Down 12.4% Since Last Earnings Report?
Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
❖Jun 4, 9:35 AMnewsvia finnhub
Honeywell Stock Is Likely to Reward Shareholders Following Quantinuum IPO, Split
HON will own a large stake in Quantinuum following the IPO.
✓Jun 3, 6:00 PMdecisionacted
Agent 2 — Adaptive — entry
Stage 2: close $171.06 > MA150 $131.61 (+30.0%), MA rising, 0.8% off 52w high, vol 1.59× avg
❖Jun 3, 3:13 PMnewsvia finnhub
Is Illumina’s (ILMN) Deeper IDT DRAGEN Tie-Up Quietly Rewriting Its Oncology Software Edge?
In May and June 2026, Integrated DNA Technologies announced a collaboration with Illumina to connect IDT’s xGen FFPE and cfDNA library prep workflows with Illumina’s DRAGEN secondary analysis platform, creating an integrated, end-to-end somatic oncology research solution that includes a new low-quality FFPE mode and compatibility with Illumina Connected Insights. This move deepens Illumina’s role in oncology by embedding its DRAGEN and interpretation software directly into high-volume IDT...
?Jun 3, 1:16 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ILMN is up ~3.95% today with no attributable headline, suggesting institutional flow or sector rotation driving the move. The absence of news is not disqualifying — real size moved this stock. With 150 minutes remaining there is sufficient time for continuation toward the +3% profit target from current levels. The macro context (T10Y2Y at 2.1σ below trend, mild yield curve flattening) is modestly unfavorable for growth/genomics names like ILMN, as defensives are favored in bear-flattening regimes, but the effect is indirect and not a strong fade catalyst. No reversal pattern is evident from the data provided — the move appears directional rather than a morning spike fading back. The primary uncertainty is the lack of a clear fundamental catalyst, which means the move could be profit-taken into the close. Overall, momentum edges the probability just above 0.5 — a borderline but actionable setup given bounded downside and time remaining.
❖Jun 3, 11:30 AMnewsvia finnhub
BioMarin (BMRN) Up 0.2% Since Last Earnings Report: Can It Continue?
BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
❖Jun 3, 10:52 AMnewsvia finnhub
ILMN Stock Jumps 98.7% in a Year: What's Powering the Surge?
Illumina shares surge 98.7% in a year as NovaSeq X adoption accelerates, clinical sequencing demand grows, and the company tops Q1 2026 guidance.
✓Jun 3, 10:44 AMdecisionacted
Agent 2 — Adaptive — entry
Stage 2: close $164.80 > MA150 $131.57 (+25.3%), MA rising, 0.7% off 52w high, vol 0.02× avg
?Jun 2, 6:00 PMdecisionconsidered
Agent 2 — Adaptive — considered
Stage 2: close $164.40 > MA150 $130.72 (+25.8%), MA rising, 0.9% off 52w high, vol 1.22× avg
❖Jun 2, 12:09 PMnewsvia finnhub
3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2026
Genomics and synthetic biology are reshaping healthcare, with growing demand for precision medicine spotlighting stocks like PACB, MYGN and TWST.
❖Jun 1, 1:11 PMnewsvia finnhub
GRAIL, Inc. (GRAL): One of the Best Stock Picks of Jeff Bezos
We just covered the Jeff Bezos Stock Portfolio: Top 10 Stock Picks and GRAIL, Inc. (NASDAQ:GRAL) ranks 8th on this list. The interest of Jeff Bezos in GRAIL, Inc. (NASDAQ:GRAL) can be understood in context of the history of Bezos as a backer of disruptive, foundational healthcare platforms that use data computing. In January 2016, […]
?Jun 1, 9:15 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ILMN is up 2.68% intraday, which represents meaningful institutional flow and conviction. However, the setup is only moderately supportive: (1) The single headline is vague and not clearly a catalyst for ILMN specifically. (2) Macro context shows a steepening yield curve (T10Y3M at 1.6σ above trend), which is mildly negative for growth/genomics names like ILMN that tend to trade on long-duration earnings expectations. (3) With 390 minutes remaining (essentially a full trading day still ahead — this appears to be early session), there is ample time for the move to extend, which is a positive factor. (4) No clear reversal pattern or fade signal is evident. The move itself is the primary evidence — someone with size pushed this up ~2.7% and that momentum has a moderate tendency to persist into the close absent a specific fade catalyst. The macro headwind from elevated short-term yields is a modest drag on high-multiple biotech/genomics. Net assessment: slight lean toward continuation but no strong conviction, placing probability just above the 0.5 threshold.
❖Jun 1, 8:58 AMnewsvia finnhub
Integrated DNA Technologies Announces End-to-End Oncology Research Workflows Optimized on Illumina Software for Faster Insights
BOULDER, Colo., June 01, 2026--IDT's library prep solutions join Illumina's extensive software ecosystem to enable streamlined analysis for IDT's FFPE and cfDNA workflows.
❖Jun 1, 6:40 AMnewsvia finnhub
1 Cash-Producing Stock Worth Investigating and 2 We Question
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.
❖Jun 1, 5:01 AMnewsvia finnhub
Integrated DNA Technologies Announces Strategic Collaboration With Illumina To Enable DRAGEN Secondary Analysis Pipeline For IDT xGen FFPE And cfDNA Next Gen Sequencing Library Preparation With Custom Panels
Integrated, push-button oncology research workflows give customers a simplified path from library prep through DRAGEN™-powered secondary analysisDRAGEN™ pipelines optimized for IDT custom hybrid capture
❖Jun 1, 4:37 AMnewsvia finnhub
Guggenheim Maintains Buy on Illumina, Raises Price Target to $180
Guggenheim analyst Subbu Nambi maintains Illumina (NASDAQ:ILMN) with a Buy and raises the price target from $170 to $180.
▣May 31, 8:00 PMjournalrotation
Agent 17 — 52-Week High Momentum closed long 23 @ $164.47 (+$34.04)
52-Week High monthly rebalance. Position retained in target set; re-entered at equal weight.
❖May 30, 12:05 PMnewsvia finnhub
Illumina Oncology Launches Put Product Depth Against Rapid Share Price Gains
Illumina (NasdaqGS:ILMN) has launched new oncology research tools, including the fully automated fireflyGO platform for targeted cancer workflows. The company has expanded its research panels for solid and blood cancers, aiming to support more precise tumor profiling. Illumina introduced its first distributed whole genome MRD research kit, validated with partners such as Mayo Clinic and highlighted with Bristol Myers Squibb at ASCO. For investors tracking Illumina, this update adds product...
✓May 29, 6:03 PMdecisionacted
Agent 6 — Options Momentum — decide: buy
CALL on ILMN — 5-day return 12.54% with close above 20-day MA ($144.39). IV 36.9%. Sized 1 contract(s) at $6.82 premium.
?May 29, 6:00 PMdecisionconsidered
Agent 2 — Adaptive — considered
Stage 2: close $162.99 > MA150 $130.29 (+25.1%), MA rising, 1.4% off 52w high, vol 1.96× avg
?May 29, 6:00 PMdecisionconsidered
Agent 1 — Immutable — considered
Stage 2: close $162.99 > MA150 $130.29 (+25.1%), MA rising, 1.4% off 52w high, vol 1.96× avg
✓May 29, 9:21 AMdecisionacted
Agent 7 — Day Trader — decide: buy
ILMN is up 5.68% intraday, a meaningful move reflecting real institutional flow. The macro backdrop is modestly supportive — the yield curve (T10Y3M at +0.8, 1.8σ above trend) is steepening, which is not directly headwinds for a genomics/life-sciences name like ILMN. Broader market tone is positive (Dow futures rising, equity market hitting highs on Iran deal optimism), which provides a favorable tailwind for risk assets including mid-cap growth/tech-adjacent names. There is no specific ILMN headline visible, suggesting this move may be driven by sector rotation or accumulated flow rather than a one-day news catalyst that could quickly reverse once priced in — that dynamic slightly favors continuation over mean-reversion. With 385 minutes remaining (over 6 hours, implying this is early-to-mid session), there is ample time for the move to extend toward the profit target. No reversal signals are evident from the data provided. The main risk is the absence of a clear catalyst making the move potentially fragile to broad market sentiment shifts, and the steepening yield curve could weigh on growth-sensitive names if rates continue to move. On balance, ordinary momentum continuation is the base case.
❖May 29, 7:56 AMnewsvia finnhub
Dow Jones Futures Rise As Dell, NetApp Surge On Earnings; Oil Falls On U.S.-Iran Deal Hopes
The stock market rose to fresh highs Thursday on a reported interim U.S.-Iran deal. Dell soared overnight on earnings.
▢May 28, 8:00 PMjournal
Agent 7 — Day Trader opened long 11 @ $158.70
▣May 28, 8:00 PMjournaltarget
Agent 7 — Day Trader closed long 11 @ $163.49 (+$52.69)
Long target: close $163.49 ≥ target $163.46
▣May 28, 8:00 PMjournaltarget
Agent 6 — Options Momentum closed long 30 @ $15.99 (+$249.66)
De-risk: premium $15.99 ≥ 2.0× entry $7.67. Selling 30/100 contracts; trailing the remainder.
▢May 28, 8:00 PMjournal
Agent 17 — 52-Week High Momentum opened long 23 @ $162.99
▢May 28, 8:00 PMjournal
Agent 6 — Options Momentum opened long 30 @ $6.82
▢May 28, 8:00 PMjournal
Agent 6 — Options Momentum opened long 70 @ $6.82
❖May 28, 5:49 PMnewsvia finnhub
Dow Jones Futures: Stock Market Hits Highs On U.S.-Iran Deal; Dell Surges On Earnings
The stock market rose to fresh highs Thursday on a reported interim U.S.-Iran deal. Dell soared overnight on earnings.
❖May 28, 12:30 PMnewsvia finnhub
Illumina and SPT Labtech unveil fireflyGO, enabling faster, simpler targeted oncology research
Illumina, Inc. (NASDAQ: ILMN) and SPT Labtech today introduced the fireflyGO automation platform, a new benchtop liquid handling and library preparation solution that brings automation, speed, and simplicity to targeted oncology research. Integrated with the MiSeq™ i100 Series, fireflyGO helps laboratories streamline workflows, expand application flexibility, and unlock genomic insights with greater efficiency. By making next-generation sequencing (NGS) more accessible, scalable, and easier to a
✓May 28, 10:55 AMdecisionacted
Agent 7 — Day Trader — decide: buy
ILMN is up ~3.9% intraday, a meaningful move reflecting real institutional flow. The product launch headline (distributed WGS solution for MRD research) provides a plausible catalyst that could sustain buying interest, as it signals commercial momentum in a high-growth application. However, the negative 'Falls Short' headline introduces some headwind and could attract selling into strength. Macro context (T10Y3M elevated at 1.8σ above trend) is more relevant to banks/recession-sensitive sectors than genomics/healthcare tools, so it's not a meaningful drag here. With 290 minutes remaining there is ample time for continuation, but also time for profit-taking. At ~3.9% up, ILMN is approaching a level where intraday longs may trim. No reversal pattern is evident from the data provided. On balance, the product launch catalyst plus the momentum signal support mild continuation, but the mixed headlines and the move already being near the top of the 2-5% range temper conviction. Assigning a modest continuation probability above the 0.5 threshold.
?May 28, 9:45 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ILMN is up 1.62% today, a modest but real move suggesting some directional flow. No news catalysts are present, which is neutral — absence of headline doesn't negate price action. The macro backdrop shows T10Y3M elevated at 1.8σ above trend, which is mildly supportive of risk-on sentiment but primarily relevant to banks and recession-sensitive sectors, not genomics/life sciences directly. With 360 minutes remaining (essentially a full session still ahead), there is ample time for the move to extend. The move magnitude (1.62%) is below the 2-5% threshold that would indicate strong institutional conviction, so this reads as ordinary momentum rather than a high-conviction breakout. No reversal signals or fade patterns are noted. Given bounded downside with the -1.5% stop and the asymmetric payoff structure, a slight lean toward continuation is warranted, but this is a low-conviction setup.
❖May 28, 9:18 AMnewsvia finnhub
3 Healthcare Stocks That Fall Short
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But speed bumps such as inventory destocking have persisted in the wake of COVID-19, limiting growth. This has capped returns as the industry’s six-month gain of 1.2% has lagged the S&P 500’s 9.8% climb.
❖May 28, 9:15 AMnewsvia finnhub
Illumina introduces the first distributed whole-genome sequencing solution for highly sensitive MRD research
Illumina, Inc. (NASDAQ: ILMN) today announced a new complete solution for molecular residual disease (MRD) research based on whole-genome sequencing (WGS). As a distributed kit, it will enable more labs to adopt MRD detection for clinical research. Now in early access for select clinical research partners, the MRD solution is the first whole-genome kit with flexibility to enable solid tumor MRD and blood cancer genomic profiling. It is the first in a new portfolio of WGS oncology research offeri
❖May 28, 5:24 AMnewsvia finnhub
Illumina Announces New Complete Solution For Molecular Residual Disease Research Based On Whole-Genome Sequencing
As a distributed kit, it will enable more labs to adopt MRD detection for clinical research. Now in early access for select clinical research partners, the MRD solution is the first whole-genome kit with flexibility to
▢May 27, 8:00 PMjournal
Agent 7 — Day Trader opened long 12 @ $156.03
▣May 27, 8:00 PMjournaltime_stop
Agent 7 — Day Trader closed long 12 @ $157.33 (+$15.66)
EOD forced close — day trader never carries overnight
✓May 27, 6:00 PMdecisionacted
Agent 6 — Options Momentum — decide: buy
CALL on ILMN — 5-day return 5.99% with close above 20-day MA ($140.66). IV 42.6%. Sized 1 contract(s) at $7.67 premium.
▢May 26, 8:00 PMjournal
Agent 6 — Options Momentum opened long 30 @ $7.67
▢May 26, 8:00 PMjournal
Agent 6 — Options Momentum opened long 70 @ $7.67
?May 21, 2:40 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ILMN is up 2.62% today with no attributable headline, suggesting institutional flow or sector rotation rather than a news spike that might fade. The macro context shows elevated 10Y breakeven inflation (2.44, +1.7σ above trend), which typically pressures long-duration growth names like ILMN — a mild headwind to continuation. However, absence of a catalyst also means no obvious catalyst exhaustion. With only 65 minutes remaining until the forced close, there is limited runway for the move to extend meaningfully to the profit target, and the macro backdrop offers a modest fade risk. No reversal signal is visible, so momentum bias is retained, but confidence is modest. Assigning a slight lean toward continuation given the asymmetric bounded risk structure, but this is a low-conviction read.
?May 15, 9:37 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
ILMN is down 1.63% with no attributable news catalyst and no macro context directly relevant to genomics/biotech. The move is modest — below the 2% threshold where momentum alone becomes highly compelling. The elevated 5Y inflation expectations (T5YIE at 2.5σ above trend) are a mild headwind for growth/biotech names as they compress multiples, providing a subtle tail to the downside. With 368 minutes remaining (well over 6 hours, suggesting this is early-to-mid session), there is ample time for the move to either extend or mean-revert. No reversal signals are evident, but no strong continuation catalyst exists either. The absence of news is neutral per framework. Given bounded risk with a -1.5% stop and +3% target, the slight macro headwind and existing momentum edge this to a 0.5 continuation probability — a marginal call to take the downside position.

← Back to dashboard